ABL1 tyrosine kinase inhibitors (TKIs) are a targeted class of drugs designed specifically to treat CML by inhibiting the kinase domain of ABL1 in the BCR-ABL1 fusion protein. This evidence concerns the gene ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive.